AU2002232536A1 - Chimeric molecules to modulate gene expression - Google Patents
Chimeric molecules to modulate gene expressionInfo
- Publication number
- AU2002232536A1 AU2002232536A1 AU2002232536A AU3253602A AU2002232536A1 AU 2002232536 A1 AU2002232536 A1 AU 2002232536A1 AU 2002232536 A AU2002232536 A AU 2002232536A AU 3253602 A AU3253602 A AU 3253602A AU 2002232536 A1 AU2002232536 A1 AU 2002232536A1
- Authority
- AU
- Australia
- Prior art keywords
- gene expression
- chimeric molecules
- modulate gene
- nucleic acid
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30418200P | 2000-11-09 | 2000-11-09 | |
US60/304,182 | 2000-11-09 | ||
PCT/US2001/047523 WO2002038738A2 (en) | 2000-11-09 | 2001-11-09 | Chimeric molecules to modulate gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002232536A1 true AU2002232536A1 (en) | 2002-05-21 |
Family
ID=23175431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002232536A Abandoned AU2002232536A1 (en) | 2000-11-09 | 2001-11-09 | Chimeric molecules to modulate gene expression |
Country Status (6)
Country | Link |
---|---|
US (3) | US20050054836A1 (en) |
EP (1) | EP1416972B1 (en) |
AT (1) | ATE544473T1 (en) |
AU (1) | AU2002232536A1 (en) |
CA (1) | CA2437942C (en) |
WO (1) | WO2002038738A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8005621B2 (en) * | 2004-09-13 | 2011-08-23 | Agency For Science Technology And Research | Transcript mapping method |
US7879992B2 (en) | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
PL2548560T3 (en) | 2005-06-23 | 2015-11-30 | Biogen Ma Inc | Compositions and methods for modulation of SMN2 splicing |
EP1937312B1 (en) | 2005-08-30 | 2016-06-29 | Ionis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
US20130004991A1 (en) * | 2006-07-21 | 2013-01-03 | Institut National De La Recherche Agronomique | Positive cytomodulines to improve bioreactor productivity |
WO2009064920A2 (en) | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8986935B2 (en) * | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
WO2010075303A1 (en) * | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
DK3305302T3 (en) | 2009-06-17 | 2018-11-19 | Biogen Ma Inc | COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLITING BY AN INDIVIDUAL |
US8927502B2 (en) | 2010-02-16 | 2015-01-06 | Icahn School Of Medicine At Mount Sinai | Embedded chimeric peptide nucleic acids and uses thereof |
WO2011103215A1 (en) * | 2010-02-16 | 2011-08-25 | Mount Sinai School Of Medicine | Embedded chimeric peptide nucleic acids and use thereof |
AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
JP5959066B2 (en) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Substituted aminobutyric acid derivatives as neprilysin inhibitors |
AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
CN104583401A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating ATP2A2 expression |
CN104540946A (en) | 2012-05-16 | 2015-04-22 | Rana医疗有限公司 | Compositions and methods for modulating UTRN expression |
EA201492123A1 (en) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE SMN GENES FAMILY |
EA201492116A1 (en) | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2 |
EP2850188A4 (en) | 2012-05-16 | 2016-01-20 | Rana Therapeutics Inc | Compositions and methods for modulating hemoglobin gene family expression |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
WO2014043544A1 (en) | 2012-09-14 | 2014-03-20 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2014110291A1 (en) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
WO2014172698A1 (en) | 2013-04-19 | 2014-10-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
JP2016531570A (en) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | Oligonucleotides targeting the euchromatin region |
WO2015051283A1 (en) | 2013-10-04 | 2015-04-09 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
MA39835A (en) | 2014-04-17 | 2017-02-22 | Biogen Ma Inc | Compositions and methods for modulation of smn2 splicing in a subject |
US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
CA2966044A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
US10410118B2 (en) | 2015-03-13 | 2019-09-10 | Deep Genomics Incorporated | System and method for training neural networks |
WO2016149455A2 (en) | 2015-03-17 | 2016-09-22 | The General Hospital Corporation | The rna interactome of polycomb repressive complex 1 (prc1) |
US10185803B2 (en) | 2015-06-15 | 2019-01-22 | Deep Genomics Incorporated | Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network |
MX2021001091A (en) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Methods for treatng huntington's disease. |
US11198867B2 (en) | 2016-06-16 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of SMN expression |
TW201839136A (en) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | Compositions and methods for the treatment of hemoglobinopathies |
US11407753B2 (en) | 2017-06-05 | 2022-08-09 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
BR112019027719A2 (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | methods to treat huntington's disease |
US11382918B2 (en) | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
JP7399870B2 (en) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス, インコーポレイテッド | Compounds to treat Huntington's disease |
JP7421507B2 (en) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス, インコーポレイテッド | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
KR20220012230A (en) * | 2019-04-24 | 2022-02-03 | 스톡 테라퓨틱스, 인크. | Methods and compositions for modulating splicing and translation |
CA3156848A1 (en) | 2019-11-01 | 2021-05-06 | Novartis Ag | The use of a splicing modulator for a treatment slowing progression of huntington's disease |
BR112022016238A2 (en) | 2020-02-28 | 2022-10-11 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO MODULATE SMN2 |
TW202304446A (en) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | The use of a splicing modulator for a treatment slowing progression of huntington’s disease |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874555A (en) * | 1987-10-30 | 1999-02-23 | California Institute Of Technology | Triple helices and processes for making same |
US6153737A (en) * | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
DK51092D0 (en) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
US5641625A (en) * | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
US6350853B1 (en) * | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
JP3053539B2 (en) * | 1995-01-19 | 2000-06-19 | 科学技術振興事業団 | CDNA for DOCK180 protein gene |
US6090947A (en) * | 1996-02-26 | 2000-07-18 | California Institute Of Technology | Method for the synthesis of pyrrole and imidazole carboxamides on a solid support |
US5998140A (en) * | 1996-07-31 | 1999-12-07 | The Scripps Research Institute | Complex formation between dsDNA and oligomer of cyclic heterocycles |
WO1998042722A1 (en) * | 1997-03-21 | 1998-10-01 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
WO1998046625A1 (en) * | 1997-04-11 | 1998-10-22 | Warner-Lambert Company | Dipeptide inhibitors of protein farnesyltransferase |
US6746868B1 (en) * | 1997-09-18 | 2004-06-08 | Isis Pharmaceuticals, Inc. | Chemical modification of DNA using peptide nucleic acid conjugates |
US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
US6656730B1 (en) * | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6033910A (en) * | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
US6559279B1 (en) * | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
MXPA05001355A (en) * | 2002-08-05 | 2005-09-30 | Atugen Ag | Further novel forms of interfering rna molecules. |
-
2001
- 2001-11-09 US US10/416,214 patent/US20050054836A1/en not_active Abandoned
- 2001-11-09 CA CA2437942A patent/CA2437942C/en not_active Expired - Fee Related
- 2001-11-09 WO PCT/US2001/047523 patent/WO2002038738A2/en not_active Application Discontinuation
- 2001-11-09 AT AT01992062T patent/ATE544473T1/en active
- 2001-11-09 EP EP01992062A patent/EP1416972B1/en not_active Expired - Lifetime
- 2001-11-09 AU AU2002232536A patent/AU2002232536A1/en not_active Abandoned
-
2010
- 2010-11-22 US US12/951,921 patent/US20110159587A1/en not_active Abandoned
-
2013
- 2013-05-23 US US13/901,476 patent/US20140011977A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2437942A1 (en) | 2002-05-16 |
ATE544473T1 (en) | 2012-02-15 |
CA2437942C (en) | 2013-06-11 |
WO2002038738A3 (en) | 2004-02-19 |
EP1416972A2 (en) | 2004-05-12 |
EP1416972B1 (en) | 2012-02-08 |
WO2002038738A2 (en) | 2002-05-16 |
US20140011977A1 (en) | 2014-01-09 |
US20110159587A1 (en) | 2011-06-30 |
EP1416972A4 (en) | 2004-09-22 |
US20050054836A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002232536A1 (en) | Chimeric molecules to modulate gene expression | |
WO1999054459A8 (en) | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | |
HUP0202442A2 (en) | Multiple cytokine-antibody complexes | |
WO2004024757A3 (en) | Modified pna molecules | |
ES2195171T3 (en) | IN VITRO TRANSPOSITION SYSTEM USING MODIFIED TN5 TRANSPOSASE. | |
ATE514783T1 (en) | PLASMID SYSTEM FOR EXPRESSING MULTIPLE GENES | |
WO2001040798A3 (en) | Methods of using randomized libraries of zinc finger proteins for the identification of gene function | |
NO20020348L (en) | Peptide acceptor ligation methods | |
ATE352638T1 (en) | REVERSE TWO-HYBRID SYSTEMS | |
AU2001270142A1 (en) | Bioengineered vehicles for targeted nucleic acid delivery | |
WO2005044976A3 (en) | Oligomeric compounds for use in gene modulation | |
AU2002365811A1 (en) | Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations | |
WO2001059149A3 (en) | Peptide biosensors for anthrax protease | |
AU2002217010A1 (en) | Peptides, the production and use thereof for binding immunoglobulins | |
IL176479A0 (en) | Methods and compositions for identifying rna-binding proteins | |
WO2004044141A3 (en) | Conjugated oligomeric compounds and their use in gene modulation | |
AU2154801A (en) | Method for linking molecular substances | |
EP0892048A3 (en) | XAF genes and polypeptides and their use for modulating apoptosis | |
WO2007047482A3 (en) | Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics | |
AU2001238212A1 (en) | Modified fluorescent proteins | |
EP1546375A4 (en) | Nucleic acids, polypeptides, and methods for modulating apoptosis | |
BR9710919A (en) | Purified protein sr-p70 | |
WO2001088124A3 (en) | Method and reagent for the inhibition of erg | |
WO2001027261A3 (en) | Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino | |
WO2001066752A3 (en) | Reproduction-specific genes |